Skip to main content

Advertisement

Table 2 Treatment outcomes for patients treated with Artemether-Lumefantrine

From: Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and K13-propeller polymorphisms in Luanda, Angola

Clinical outcome Total Age group
Initially selected 122 28 ≤ 5 years 94 > 5 years
Number of patients: n
 PCR uncorrected responses    
  Withdrawn + Lost, n (%) 19 (15.6) 7 (25) 12 (12.8)
  Eligible; n (%) 103 (100) 21 (20.4) 82 (79.6)
  Global failure; n (%) 10 (9.7) 5 (23.8) 5 (6.1)
  ETF; n (%) 1 (1 %) 1 (4.8) 0
  LCF; n (%) 1 (1) 0 1 (1.2)
  LPF; n (%) 8 (7.8) 4 (19) 4 (4.9)
  ACPR; n (%) 93 (90.3) 16 (76.2) 77 (94)
 PCR corrected responses
  Eligible; n (%) 103 (100) 21 (20.4) 82 (78.6)
  Global Failure; n (%) 9 (8.7) 5 (24) 4 (5)
  ACPR; n (%) 94 (91.2) 16 (76) 78 (95)
  Recrudescence; n (%) 2 (1.9) 1 (4.8) 1 (1.2)
  Reinfection; n (%) 1 (1) 0 1 (1.2)
  1. PCR polymerase chain reaction, n number of patients, ACPR adequate clinical and parasitological response, ETF early treatment failure, LTF late treatment failure